Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group.

Session ID: 2025-08-17:f7ea570de1931b201e2bf810 Player Element ID: vjs_video_3 ...

Semaglutide 2.4 mg outperformed placebo in MASH resolution (62.9% vs. 34.1%) and improvement in fibrosis (37% vs. 22.5%) at 72 weeks. Safety profile was consistent with previous phase 2 trials.

At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group.